"Our strength is in our breadth"
- MCCA
Australia's medicinal cannabis sector exists because patients and families fought for it. The advocacy that led to legalisation was grounded in compassion, lived experience, and a simple belief: people in pain deserve access to medicine that works for them.
That origin story matters - because the sector is now at a crossroads. Nearly one million prescription applications were authorised in 2024 alone. Over 1,000 products are on the market. The merger of AMCA and MCIA into the Medicinal Cannabis Council Australia signals that the sector is ready to professionalise.
But growth without governance creates risk. When profit motives operate without clear principles, the result is predictable: volume-driven prescribing, advertising breaches, and a widening gap between the sector's ethical origins and its commercial reality. The concern isn't industry itself - industry creates access, employment, research investment, and innovation. The concern is unprincipled engagement where commercial incentives override patient safety.
The opportunity is an aligned sector: industry, community, health, and research working within a shared governance framework where everyone benefits from the paradigm - patients get safer access, prescribers get clinical support, researchers get data, industry gets credibility, and regulators get a partner instead of a problem.
Industry aligned with community, health, and research. Transparent governance. Agreed language. Patient voice at the table - not as consultation theatre, but as structural authority. A sector where ethical operators are rewarded and the standard is high enough that everyone benefits from the paradigm shift.
This is what a peak body exists to build.
Growth without governance. 72,000 scripts from a single doctor. Advertising enforcement as the only accountability mechanism. No adverse event monitoring. No agreed language for risk. Patient voices filtered through commercial interests. A sector that loses public trust before it has the chance to prove its value.
This is the trajectory without intervention.
The standard: "Not harm free. Not without risk. Carefully and safely."
Not zero-risk absolutism. Not unregulated commercial growth. A sector that acknowledges risk, governs it transparently, and keeps the patient at the centre. The families who fought for legalisation - the Haslams and thousands like them - didn't fight for an unregulated market. They fought for safe, affordable, principled access.
MCCA has identified three priority areas: driving and employment law reform, patient access and affordability, and industry advocacy. All three depend on evidence the sector currently cannot produce.
Driving law reform requires data showing medicinal cannabis patients are not impaired - that data doesn't exist nationally. Employment protections require evidence of legitimate medical use and functional capacity - that evidence is scattered across individual clinics. Patient access arguments need cost-effectiveness data and treatment outcome evidence.
An ethical industry that captures and shares outcome data builds the evidence base that makes every other advocacy goal achievable. Governance first, then the data flows, then the advocacy has weight.
The MCCA merger creates an opportunity to build the infrastructure the sector hasn't had before. These aren't criticisms - they're the natural next steps for a maturing industry. Other countries have started building some of these. Australia's scale and regulatory sophistication means we could do it better.
The TGA's SAS-B and Authorised Prescriber pathways were designed to manage access, not generate evidence. Prescribers submit clinical justifications and product details, but no outcome data is required or collected. AP prescribers report only aggregate patient counts every six months. The result: 979,000 prescription applications with essentially no national data on whether those prescriptions helped.
This isn't a failure of the TGA - it wasn't designed for this. But it means the sector has an enormous opportunity: build the outcomes layer that turns every prescription into a research data point.
Every cannabis prescription is already a personalised experiment. "Find your dose" is the clinical reality - the endocannabinoid system varies between individuals and dose-response is non-linear. Each patient's journey is an N-of-1 trial. The infrastructure to capture that data at national scale would be globally significant.
A co-designed communications charter would give the sector a common voice - agreed language for talking about risk, safety, patient information, and the value of principled medicinal access. This protects ethical operators, supports prescribers, and builds public trust. The mental health sector did this through the National Communications Charter, which Ed led nationally across all 31 Primary Health Networks.
The sector was founded on patient advocacy. As it professionalises, ensuring that patient and community voices retain structural authority - not just a seat at the table but a hand on the governance - keeps the sector honest and grounded in its origins. MCCA's breadth (patients, prescribers, industry, researchers) is a strength. The architecture to channel that breadth into coherent governance is the next step.
3,000+ authorised prescribers could benefit from an independent knowledge translation layer - connecting international research findings to Australian clinical practice. MCCA's existing TEACH-HUB and COMPASS programs are a foundation. Building on these with structured, evidence-based prescriber support (independent of commercial sponsors) would strengthen prescriber confidence and patient outcomes.
The sector's long-term viability depends on public trust. A comprehensive, member-driven code of conduct - going beyond advertising to cover prescribing ethics, telehealth quality, and patient safety - would differentiate ethical operators, attract investment, and give regulators confidence. This is how a sector earns the data and credibility it needs to eventually address driving and employment law reform.
Five stakeholder groups, a pentagon, each feeding the next in a cyclical flow. Signals move inward: patient-reported outcomes, prescriber observations, pharmacy dispensing data, research findings, and regulatory intelligence. They flow outward: clinical decision support, safety alerts, prescriber education, and research-grade datasets - calibrated by role and need. The same infrastructure that detects adverse events also captures the outcome data that makes real-world evidence possible.
This is not a surveillance system. It is a learning system - one where every prescription generates evidence, every patient outcome contributes to the knowledge base, and the sector gets collectively smarter over time. The research paradigm that fits personalised medicine: mixed methods, patient-reported outcomes, N-of-1 data aggregated at population scale.
The person using medicinal cannabis is the first voice. Patient-reported outcomes, adverse events, and experience data are the foundation of safety governance. Not filtered through commercial interpretation. Not delayed by institutional processes. Direct, structured, and respected.
GPs, specialists, and nurse practitioners - AHPRA-governed clinicians making prescribing decisions. They need clinical decision support, adverse event alerts, and prescriber learning networks. Currently self-educating through conferences and company materials with commercial conflicts.
The supply and dispensing layer - community pharmacists, compounding pharmacists, and pharmacy networks. Product quality signals, batch-level tracking, interaction alerts. Pharmacists are the last safety checkpoint before the patient.
Evidence synthesis and pattern detection. University research groups and clinical networks. Every prescription generates potential research data, but the TGA access system wasn't designed to capture outcomes. This vertex connects the learning system to Australia's research capability - turning individual N-of-1 patient journeys into population-level evidence.
TGA, state health departments, AHPRA, Pharmacy Board. The regulatory layer receives safety intelligence and translates it into product standards, prescribing guidance, and enforcement. In this architecture, regulation is informed by every other vertex - not operating in isolation.
National event monitoring and signal detection. Research-grade real-world evidence from structured patient outcomes. Tiered information sharing calibrated by role. Agreed sector language through a co-designed communications charter. Independent patient voice with structural governance authority. A data architecture where every prescription contributes to the evidence base - turning personalised medicine into population-level knowledge.
A replacement for TGA or the Lambert Initiative. A commercial platform. An extension of any single company's infrastructure. A surveillance system that watches from above. It is a learning system the sector co-designs and the peak body stewards - where data flows because participants trust the governance, not because they're compelled.
"Find your dose" is the clinical reality of medicinal cannabis. Every patient works with their prescriber to trial products, adjust doses, and track what works for them. That process is an N-of-1 trial - a single-patient experiment where the individual is both subject and beneficiary.
Right now, those individual experiments generate no shared evidence. But if structured outcome data were captured - even from a fraction of Australia's prescriptions - the combined picture would be transformative. Individual N-of-1 data aggregates into population-level evidence. Mixed methods research (patient-reported outcomes, prescriber observations, product-level tracking) produces the kind of evidence that RCTs alone struggle to generate for personalised medicine.
The UK's Project Twenty21 proved this with 20,000 patients. Australia's prescription volume is 50 times larger. The infrastructure to capture and share that evidence is the missing piece - not the methodology.
| Traditional RCTs alone | Combined approach (RCTs + learning system) | |
|---|---|---|
| Scale | 50-500 patients per trial | 100,000+ patients contributing data continuously |
| Products | 1-2 standardised per trial | All products in market, real prescribing patterns |
| Personalisation | Population averages | Individual response trajectories (N-of-1) |
| Cost per insight | $10,000-50,000 per patient | Marginal cost of structured data capture |
| What it answers | "Does this product work on average?" | "What works for whom, and under what conditions?" |
The TGA rescheduled psilocybin and MDMA in 2023 based on the totality of international evidence - not completed Australian Phase 3 RCTs. The same principle applies to cannabis: broader evidence packages, grounded in real-world data, can inform regulation. The infrastructure to generate that evidence is the opportunity.
The governance patterns proposed here are not theoretical. They have been built, operated, and published in Australia's alcohol and other drugs sector - and the person presenting this concept was directly involved in building them.
NCCRED / UNSW Sydney · 2019-2025
Australia's national drug alert and early warning system. Multi-jurisdictional, multi-stakeholder, rapid response. Co-designed with peer organisations (AIVL, NUAA, Harm Reduction Victoria). 85 subscriber organisations across all Australian jurisdictions. Not just surveillance - the PRN generated research-grade signal data, published peer-reviewed findings, and built the evidence base for national drug policy.
Everymind (NSW Health) · 2022-2024
The national standard for safe mental health communication. Agreed-upon language across the sector. Co-designed with stakeholders. Signatory model - organisations opt in, creating sector accountability.
These aren't claims. They're published, peer-reviewed, and open access.
The Harm Reduction Hub is a working concept document that demonstrates this governance architecture applied to Australia's drug harm reduction sector. It was shared with AIVL's CEO in March 2026.
View the Harm Reduction Hub → Full publications →Not a strategy deck. Not a consulting engagement. The CEO who builds this should be the same person who shaped the architecture. Hands-on means: writing the brief, chairing the co-design, commissioning the infrastructure, and presenting to the TGA.
This sector was built by people who showed up - Lucy Haslam, the prescribers who took the early risk, the patients who told their stories. The governance layer should be built the same way: by someone who has built community organisations from the ground up, coordinated national stakeholder networks through influence rather than authority, and published the evidence alongside the practitioners they worked with. Someone who understands that a peak body's strength comes from its members, and that members engage when governance is built with them, not imposed on them.
Systems builder. Harm reduction. Governance. Evidence.
I was in composite 1-2 class with Dan Haslam. My brother uses medicinal cannabis for head injuries. This isn't an abstract policy interest for me.
When I saw the MCCA CEO role posted, I felt the alignment immediately. I reached out to Lucy, we spoke, and the conversation confirmed what I'd sensed: the sector's origin is compassion and patient voice, but the governance infrastructure hasn't kept pace with the growth.
Harm reduction here works in both directions. It's about monitoring cannabis safety, yes - but it's also about what principled medicinal access prevents. When people can't access regulated treatment pathways, they find alternatives. Some turn to off-label prescription medications. Some turn to unregulated sources. The nitazene crisis my PRN work tracked nationally showed exactly where that leads - synthetic opioids appearing in substances people didn't know contained them, because regulated pathways weren't accessible or affordable. Principled medicinal cannabis access is itself a form of harm reduction.
My career has been about building communities and the systems that serve them. In Medellín, I founded and led Primed Community for ten years - over 1,000 participants across four comunas, 600+ documented events including a Conversemos panel on cannabis awareness and a cultivation workshop. Those were community conversations about substances, risk, and the difference between prohibition and principled regulation. Nationally, I coordinated 85 organisations across the PRN and presented the National Communications Charter to all 31 Primary Health Networks. In both cases, the work was hands-on: I built the systems, ran the governance, published the evidence, and showed up.
This concept document is the same approach. I built it because I believe the person who leads MCCA should be the kind of person who builds things - not someone who commissions a consultancy, but someone who understands the architecture because they've already shaped it in another sector.
This concept document was built independently. It is not commissioned by or affiliated with MCCA, AMCA, MCIA, or any medicinal cannabis organisation. It represents a vision for what the sector's governance infrastructure could look like, informed by direct experience building equivalent systems in Australia's alcohol and other drugs sector.